PDX Pharmaceuticals started in 2010 as a spinoff from the Biomedical Engineering Department at OHSU. The company has developed novel cancer therapeutics by combining nanotechnology and cancer systems biology in collaboration with the Knight Cancer Institute (KCI) of OHSU.
PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE) and is raising $15M to initiate the clinical trial of AIRISE in 2022 and advance ARAC to clinics by 2023.Nanoparticle platform for co-delivering siRNA, drugs, vaccines, and/or immunotherapies. This proprietary nanoparticle can load multiple cargo types at once and is capable of targeted delivery to solid tumors upon intravenous administration.
PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE) and is raising $15M to initiate the clinical trial of AIRISE in 2022 and advance ARAC to clinics by 2023.Nanoparticle platform for co-delivering siRNA, drugs, vaccines, and/or immunotherapies. This proprietary nanoparticle can load multiple cargo types at once and is capable of targeted delivery to solid tumors upon intravenous administration.
Services
Dr. Yantasee earned a doctorate in Chemical Engineering and a Master of Business Administration from Oregon State University. From 2001-2008, she worked as a scientist at Pacific Northwest National Laboratory (DoE National Lab). She is currently a professor with tenure in Biomedical Engineering at Oregon Health and Science University, where she is recognized as an Oregon Nanomedicine Signature Researcher.
Reviews
Be the first to review PDX Pharmaceuticals.
Write a Review
